Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.68 |
| ▸ | DDB1 | Q16531 | 18/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29277065 | 0.88 | CRBN (0.54) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL25188462 | 0.83 | HSD17B10 (0.48) | CRBNDDB1POLB | |
| SCHEMBL26925285 | 0.82 | DDB1 (0.65) | CRBNDDB1POLB | |
| SCHEMBL30706220 | 0.82 | DDB1 (0.65) | CRBNDDB1POLB | |
| SCHEMBL8190472 | 0.81 | CRBN (0.70) | CRBNDDB1POLB | |
| SCHEMBL31704153 | 0.81 | CRBN (1.00) | CRBNDDB1POLB | |
| SCHEMBL2107934 | 0.81 | CRBN (1.00) | CRBNDDB1POLB | |
| SCHEMBL31704110 | 0.81 | CRBN (1.00) | CRBNDDB1POLB | |
| SCHEMBL29021259 | 0.80 | CRBN (0.62) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL19370870 | 0.79 | CRBN (0.81) | CRBNDDB1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709730-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Celgene Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| CN-119907792-A | Benzyl or thiophene methylene substituted aminoquinazoline derivatives and their use as SOS1 degradants | 领泰生物医药(绍兴)有限公司 | 2025-04-29 | — | — | CN | disclosed |
| WO-2024233742-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | CELGENE CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240261418-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2024-08-08 | — | — | US | disclosed |
| US-20240261417-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2024-08-08 | — | — | US | disclosed |
| WO-2024083255-A1 | BENZYL OR THIENYLMETHYLENE-SUBSTITUTED AMINOQUINAZOLINE DERIVATIVE AND USE THEREOF AS SOS1 DEGRADATION AGENT | 上海领泰生物医药科技有限公司 | 2024-04-25 | — | — | WO | disclosed |
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| CN-115232114-B | SOS1 degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-115232114-A | SOS1 degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115232111-A | SOS1 degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115232108-A | SOS1 degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261418-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SOS1, RAC1, RSU1 | CRBN 802/4885DDB1 1803/4885POLB 3530/4885 |
| US-20240261417-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | RAC1, SOS1, RSU1 | CRBN 606/4885DDB1 1921/4885POLB 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.